Sekar Kathiresan
2022
In 2022, Sekar Kathiresan earned a total compensation of $7.8M as Chief Executive Officer at Verve Therapeutics, a 41% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $315,744 |
|---|---|
| Option Awards | $6,947,166 |
| Salary | $571,320 |
| Other | $12,488 |
| Total | $7,846,718 |
Kathiresan received $6.9M in option awards, accounting for 89% of the total pay in 2022.
Kathiresan also received $315.7K in non-equity incentive plan, $571.3K in salary and $12.5K in other compensation.
Rankings
In 2022, Sekar Kathiresan's compensation ranked 361st out of 5,760 executives tracked by ExecPay. In other words, Kathiresan earned more than 93.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 361 out of 5,760 | 94th |
Division Manufacturing | 144 out of 3,136 | 95th |
Major group Chemicals And Allied Products | 37 out of 1,422 | 97th |
Industry group Drugs | 26 out of 1,323 | 98th |
Industry Pharmaceutical Preparations | 18 out of 969 | 98th |
Source: SEC filing on April 28, 2023.
Kathiresan's colleagues
We found two more compensation records of executives who worked with Sekar Kathiresan at Verve Therapeutics in 2022.